XW143G8Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- Billable / Specific Code
XW143G8 is a billable ICD-10-PCS procedure code for Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRGs 016, 017. The root operation Transfusion involves putting in blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 1 | Transfusion |
| 4 | BodyPart | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | G | Atidarsagene Autotemcel |
| 7 | Qualifier | 8 | New Technology Group 8 |
Code History
- 30243C0 — Transfuse Autol HSPC, Gene Mod in Central Vein, Perc
Similar Procedure Codes
Questions About XW143G8
Is XW143G8 a billable code?
Yes. XW143G8 is a complete seven-character ICD-10-PCS code, specific enough to report Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW143G8 mean?
XW143G8 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 1 is the Operation (Transfusion); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character G is the Device/Substance/Technology (Atidarsagene Autotemcel); the 7th character 8 is the Qualifier (New Technology Group 8).
What MS-DRG does XW143G8 group to?
On an inpatient stay, Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 maps to MS-DRGs 016, 017, with relative weights from 4.8383 to 5.9297. The MS-DRG sets the fixed Medicare payment for the stay.
